SCYNEXIS (SCYX)
(Delayed Data from NSDQ)
$1.51 USD
-0.02 (-1.31%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $1.52 +0.01 (0.66%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth D Momentum C VGM
Brokerage Reports
0 items in cart
SCYNEXIS, Inc. [SCYX]
Reports for Purchase
Showing records 21 - 40 ( 66 total )
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Ibrex Shows Consistent Efficacy in Refractory Infections; Still Upside to Our Model; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Financing Extends Cash Runway Through Expected Mid-2021 Ibrex aVVC Approval and rVVC Phase 3 Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Acute VVC Phase 3s Ahead of Schedule; Now Expect U.S. Data by Year-End and Global Study Early 2Q20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Recurrent VVC Phase 3 Ready to Go With SPA; Funded Through Low-Risk 1H20 Acute VVC Data and Filing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Ibrexafungerp Increasingly Relevant in Increasingly Resistant Fungal Infections; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
4Q18 Results; VVC Phase 3s and Potential LPAD Enabling Studies Ongoing; Pivotal Data 1H20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
VVC Phase 3 Plans Check Out With FDA; Consistent With Our Projections; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
We are transferring coverage due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Healthcare: Coverage Update
Provider: Roth Capital Partners, Inc.
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
2Q18 Results; We?re Scrapping IV for Now, But Undervalued on Oral for VVC Alone; Reiterate Buy; Lower to $4.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
2Q18 Reported; Oral SCY-078 Advances While IV Development Continues
Provider: Roth Capital Partners, Inc.
Analyst: LEBOYER R
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Corrected - Phase 2b Study Shows Positive Results; Dose Level For Phase 3 Selected
Provider: Roth Capital Partners, Inc.
Analyst: LEBOYER R
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Best-Case Phase 2b Outcome in VVC; Heading Into Phase 3
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Phase 2b Study Shows Positive Results; Dose Level For Phase 3 Selected
Provider: Roth Capital Partners, Inc.
Analyst: LEBOYER R
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Fighting the Fungus Among Us; Assume With Buy and $5 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O